vs
Orthofix Medical Inc.（OFIX）与Paylocity Holding Corp（PCTY）财务数据对比。点击上方公司名可切换其他公司
Paylocity Holding Corp的季度营收约是Orthofix Medical Inc.的1.8倍（$387.0M vs $219.9M），Paylocity Holding Corp净利率更高（13.0% vs -1.0%，领先14.0%），Paylocity Holding Corp同比增速更快（11.3% vs 2.0%），Paylocity Holding Corp自由现金流更多（$113.6M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Paylocity Holding Corp是美国领先的云端人力资源管理服务商，核心产品覆盖薪资核算、支出管理及人力资本管理（HCM）类SaaS软件，可帮助不同规模的企业客户优化人力与财务相关运营流程，有效提升管理效率、降低运营成本。
OFIX vs PCTY — 直观对比
营收规模更大
PCTY
是对方的1.8倍
$219.9M
营收增速更快
PCTY
高出9.3%
2.0%
净利率更高
PCTY
高出14.0%
-1.0%
自由现金流更多
PCTY
多$96.8M
$16.8M
两年增速更快
OFIX
近两年复合增速
2.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $387.0M |
| 净利润 | $-2.2M | $50.2M |
| 毛利率 | 71.1% | 72.9% |
| 营业利润率 | 0.2% | 18.2% |
| 净利率 | -1.0% | 13.0% |
| 营收同比 | 2.0% | 11.3% |
| 净利润同比 | 92.4% | 34.0% |
| 每股收益（稀释后） | $-0.05 | $0.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPCTY
| Q4 25 | $219.9M | $387.0M | ||
| Q3 25 | $205.6M | $378.9M | ||
| Q2 25 | $203.1M | $369.9M | ||
| Q1 25 | $193.6M | $421.1M | ||
| Q4 24 | $215.7M | $347.7M | ||
| Q3 24 | $196.6M | $333.1M | ||
| Q2 24 | $198.6M | $324.7M | ||
| Q1 24 | $188.6M | $366.8M |
净利润OFIXPCTY
| Q4 25 | $-2.2M | $50.2M | ||
| Q3 25 | $-22.8M | $48.0M | ||
| Q2 25 | $-14.1M | $48.6M | ||
| Q1 25 | $-53.1M | $91.5M | ||
| Q4 24 | $-29.1M | $37.5M | ||
| Q3 24 | $-27.4M | $49.6M | ||
| Q2 24 | $-33.4M | $48.8M | ||
| Q1 24 | $-36.0M | $85.3M |
毛利率OFIXPCTY
| Q4 25 | 71.1% | 72.9% | ||
| Q3 25 | 72.2% | 73.9% | ||
| Q2 25 | 68.7% | 73.5% | ||
| Q1 25 | 62.8% | 77.1% | ||
| Q4 24 | 69.0% | 72.6% | ||
| Q3 24 | 68.7% | 74.4% | ||
| Q2 24 | 67.8% | 74.0% | ||
| Q1 24 | 67.5% | 77.8% |
营业利润率OFIXPCTY
| Q4 25 | 0.2% | 18.2% | ||
| Q3 25 | -8.3% | 19.6% | ||
| Q2 25 | -7.9% | 17.9% | ||
| Q1 25 | -25.2% | 30.2% | ||
| Q4 24 | -5.3% | 13.4% | ||
| Q3 24 | -9.6% | 19.3% | ||
| Q2 24 | -12.5% | 19.4% | ||
| Q1 24 | -15.6% | 29.0% |
净利率OFIXPCTY
| Q4 25 | -1.0% | 13.0% | ||
| Q3 25 | -11.1% | 12.7% | ||
| Q2 25 | -6.9% | 13.1% | ||
| Q1 25 | -27.4% | 21.7% | ||
| Q4 24 | -13.5% | 10.8% | ||
| Q3 24 | -13.9% | 14.9% | ||
| Q2 24 | -16.8% | 15.0% | ||
| Q1 24 | -19.1% | 23.3% |
每股收益（稀释后）OFIXPCTY
| Q4 25 | $-0.05 | $0.92 | ||
| Q3 25 | $-0.57 | $0.86 | ||
| Q2 25 | $-0.36 | $0.87 | ||
| Q1 25 | $-1.35 | $1.61 | ||
| Q4 24 | $-0.76 | $0.66 | ||
| Q3 24 | $-0.71 | $0.88 | ||
| Q2 24 | $-0.88 | $0.85 | ||
| Q1 24 | $-0.95 | $1.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $162.5M |
| 总债务越低越好 | — | $81.3M |
| 股东权益账面价值 | $450.0M | $1.1B |
| 总资产 | $850.6M | $7.0B |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPCTY
| Q4 25 | $82.0M | $162.5M | ||
| Q3 25 | $62.9M | $165.2M | ||
| Q2 25 | $65.6M | $398.1M | ||
| Q1 25 | $58.0M | $477.8M | ||
| Q4 24 | $83.2M | $482.4M | ||
| Q3 24 | $30.1M | $778.5M | ||
| Q2 24 | $26.4M | $401.8M | ||
| Q1 24 | $27.0M | $492.7M |
总债务OFIXPCTY
| Q4 25 | — | $81.3M | ||
| Q3 25 | $157.2M | $81.3M | ||
| Q2 25 | $157.0M | $162.5M | ||
| Q1 25 | $156.9M | $243.8M | ||
| Q4 24 | $157.0M | $325.0M | ||
| Q3 24 | $118.5M | $325.0M | ||
| Q2 24 | $118.0M | $0 | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPCTY
| Q4 25 | $450.0M | $1.1B | ||
| Q3 25 | $442.5M | $1.1B | ||
| Q2 25 | $458.3M | $1.2B | ||
| Q1 25 | $458.3M | $1.2B | ||
| Q4 24 | $503.1M | $1.2B | ||
| Q3 24 | $525.9M | $1.1B | ||
| Q2 24 | $546.0M | $1.0B | ||
| Q1 24 | $570.3M | $1.1B |
总资产OFIXPCTY
| Q4 25 | $850.6M | $7.0B | ||
| Q3 25 | $832.6M | $4.2B | ||
| Q2 25 | $837.2M | $4.4B | ||
| Q1 25 | $823.1M | $5.2B | ||
| Q4 24 | $893.3M | $5.3B | ||
| Q3 24 | $867.9M | $4.0B | ||
| Q2 24 | $882.0M | $4.2B | ||
| Q1 24 | $906.0M | $5.0B |
负债/权益比OFIXPCTY
| Q4 25 | — | 0.07× | ||
| Q3 25 | 0.36× | 0.07× | ||
| Q2 25 | 0.34× | 0.13× | ||
| Q1 25 | 0.34× | 0.20× | ||
| Q4 24 | 0.31× | 0.28× | ||
| Q3 24 | 0.23× | 0.29× | ||
| Q2 24 | 0.22× | 0.00× | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $117.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $113.6M |
| 自由现金流率自由现金流/营收 | 7.6% | 29.4% |
| 资本支出强度资本支出/营收 | 4.9% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 2.33× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $461.1M |
8季度趋势，按日历期对齐
经营现金流OFIXPCTY
| Q4 25 | $27.7M | $117.0M | ||
| Q3 25 | $12.4M | $86.5M | ||
| Q2 25 | $11.6M | $86.6M | ||
| Q1 25 | $-18.4M | $186.0M | ||
| Q4 24 | $23.7M | $54.2M | ||
| Q3 24 | $11.7M | $91.5M | ||
| Q2 24 | $9.0M | $79.9M | ||
| Q1 24 | $-18.6M | $167.5M |
自由现金流OFIXPCTY
| Q4 25 | $16.8M | $113.6M | ||
| Q3 25 | $2.5M | $82.7M | ||
| Q2 25 | $4.5M | $81.1M | ||
| Q1 25 | $-25.1M | $183.7M | ||
| Q4 24 | $15.2M | $51.2M | ||
| Q3 24 | $6.3M | $89.1M | ||
| Q2 24 | $-360.0K | $73.6M | ||
| Q1 24 | $-29.1M | $162.0M |
自由现金流率OFIXPCTY
| Q4 25 | 7.6% | 29.4% | ||
| Q3 25 | 1.2% | 21.8% | ||
| Q2 25 | 2.2% | 21.9% | ||
| Q1 25 | -13.0% | 43.6% | ||
| Q4 24 | 7.0% | 14.7% | ||
| Q3 24 | 3.2% | 26.8% | ||
| Q2 24 | -0.2% | 22.7% | ||
| Q1 24 | -15.4% | 44.2% |
资本支出强度OFIXPCTY
| Q4 25 | 4.9% | 0.9% | ||
| Q3 25 | 4.8% | 1.0% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 3.5% | 0.5% | ||
| Q4 24 | 4.0% | 0.9% | ||
| Q3 24 | 2.7% | 0.7% | ||
| Q2 24 | 4.7% | 1.9% | ||
| Q1 24 | 5.6% | 1.5% |
现金转化率OFIXPCTY
| Q4 25 | — | 2.33× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 1.78× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 1.84× | ||
| Q2 24 | — | 1.64× | ||
| Q1 24 | — | 1.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
